Azithromycin 250 mg x3/week (3 tablets/week) + Hydroxychloroquine + Prednisone for lung diseases, interstitial

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Mar 2026: Trial registered, NCT07443436

The trials

NCT07443436: Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants

State
Not started
Phase
Phase 2
People
30 planned
Started
1 Nov 2026
Primary completion
1 Nov 2027
Arms
Prednisone 10 mg/day -Hydroxychloroquine 400 mg/day - Azithromycin 250mg*3
Results
None posted
  1. 2 Mar 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.